Table 2.

Clinical studies on the reviewed smart nanoparticles (NPs).

Delivery System Platform	Nanoparticles	Clinical Study
Dendritic polymers	DEP™-Docetaxel DTX-SPL8783 [128] (DEP dendrimer with docetaxel and PEG terminal blocks)	Advanced or metastatic cancer
	VivaGel® SPL7013 [128] (an active ingredient is a generation 4 lysine dendrimer, ended by a 2-[(3,6-disulfo-1-naphthalenyl)oxy] acetic acid disodium salt)	Bacterial vaginosis
	Hydroxyl-terminated PAMAM dendrimers [129]	Neuroinflammation in a large animal
Polyelectrolytes	Protamines [130]	Approved by the FDA for clinical applications, including insulin delivery and reverting heparin-induced anticoagulation.
Cyclic polymers	An anticancer agent CALAA01, a targeted, self-assembling nanoparticles system based on CD complexed siRNA [131] Piroxicam-beta-Cyclodextrin [132] Nimesulide-beta-Cyclodextrin [132] Aceclofenac-beta-Cyclodextrin [132]	In phase I clinical trials for the treatment of solid tumours Anti-inflammation Anti-inflammation Anti-inflammation